Detraxi

Detraxi is a biotechnology company specializing in the development of a proprietary platform technology designed to improve organ transplantation outcomes and treat critical care conditions. The company's lead technology is a multifunctional, polymer-based solution that addresses ischemia-reperfusion injury and extends the viability of donor organs. Beyond transplantation, Detraxi is exploring applications in hemorrhagic shock, traumatic brain injury, and various regenerative medicine fields. In May 2023, Detraxi was acquired by Aeterna Zentaris, which now oversees the clinical development of its pipeline. The platform's unique mechanism focuses on stabilizing cellular integrity and mitigating the inflammatory response during physiological stress.